JMP Securities downgraded T-cell therapy developer Adicet Bio (NASDAQ:ACET) to market perform and removed its price target of $19, citing uncertainty about the start date for a pivotal study for the ...

Investing.com - Citizens JMP has reiterated its Market Outperform rating and $5.00 price target on Teads Holding (NASDAQ:TEAD), a digital advertising company with a market capitalization of $160.5 ...